{
    "nctId": "NCT01008904",
    "briefTitle": "Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer",
    "officialTitle": "A Pilot Phase II Trial of Magnesium Supplements to Reduce Menopausal Hot Flashes in Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cancer Survivor, Hot Flashes, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets 1 of the following criteria:\n\n  * History of breast cancer (currently without malignant disease)\n  * No history of breast cancer but wishes to avoid estrogen due to a perceived increased risk of breast cancer\n* Must have bothersome hot flashes (defined by their occurrence of \u2265 14 times per week and of sufficient severity to make the patient desire therapeutic intervention) for \u2265 1 month before study entry\n* Has undergone treatment for cancer (patients other than breast cancer survivors are eligible)\n\nPATIENT CHARACTERISTICS:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Creatinine clearance \u2265 30 mL/min\n* No hypersensitivity to magnesium oxide\n* No medical or other condition(s) that, in the opinion of the investigator/sub-investigator, may compromise the objectives of the study\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, progestational agents, or gabapentin\n* More than 28 days since prior and no other concurrent investigational drugs\n* Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed provided patient has been on a constant dose for \\> 4 weeks AND is not expected to stop the medication during the study period",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}